Fibrosis, Post-COVID Syndrome, Post-traumatic Stress Disorder, Sequelae
Conditions
Brief summary
From July to September 2020, in a first uncontrolled cohort study, 478 patients who were hospitalized at Bicêtre hospital for COVID-19 and who survived were evaluated at 4 months (publication accepted at JAMA). The current project aims to bring together the means to continue this work during the 2nd epidemic wave.
Detailed description
From 15th July to 18th September, 2020, in a first uncontrolled cohort study (Multi-Expertise Consultation of Bicêtre After Covid-19, COMEBAC), we evaluated at four months the surviving patients who were hospitalized at the Bicêtre hospital for COVID-19 during the 1st wave of the epidemic in France and having survived this hospitalization. This cohort included 478 patients. The article resulting from the analysis of the data collected is accepted for publication in JAMA. This evaluation, the aim of which was both clinical and scientific, was carried out largely thanks to human and material resources then demobilized because of the epidemic and thanks to the investment of doctors and psychologists who carried out the work in addition to their usual work. The response to the current call for projects aims to bring together the means to continue this monitoring work during the 2nd epidemic wave, while the means and staff are this time completely mobilized by the care of patients with COVID-19 and other. It also aims to raise funds that will allow an in-depth analysis of the residual symptoms presented by the patients. The current project aims to continue the work started with the COMEBAC 1st wave cohort with: * The inclusion of patients hospitalized after the 1st wave. * An assessment of symptoms according to the SARS-CoV-2 variant. * A 12-month follow-up of symptomatic patients during the evaluation in COMEBAC 1st wave.
Interventions
OTHERTeleconsultation
Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms: * General signs: Anorexia, fatigue, new hospitalization, weight loss, * Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge * Neurological signs: headache, paraesthesia, anosmia, limb paralysis * Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting Edition 2021 ◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties
OTHEROutpatient clinic
During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment. * General clinical examination * Assessment of the state of health * Respiratory assessment * Pulmonary CT assessment * Cognitive evaluation * Cardiological evaluation * Renal assessment * Immunological evaluation
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For the 6-month evaluation of patients from the 2nd epidemic wave * Inclusion criteria * Age ≥18 years old * COVID-19 defined either by a reverse transcriptase-polymerase chain reaction (RT-PCR) or by a combination of clinical signs and compatible lung CT scan * Hospitalization for COVID-19 after 1st July 2020 * Living out of the hospital *
Exclusion criteria
* Death occurring between index hospitalization and reassessment * Patient refusal * Discovery of a positive RT-PCR for SARS-CoV-2 during hospitalization for a reason other than COVID-19 * Nosocomial COVID-19 For the 12-month evaluation of patients from the 1st epidemic wave * Inclusion criteria ◌ Presence of general, cognitive, psychological and respiratory symptoms during the assessment made at 4 months in COMEBAC 1st wave *
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of respiratory, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19. | 6 months | nature and prevalence of symptoms persisting at 6 months of an episode of COVID-19 requiring hospitalization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference between the prevalence of residual symptoms between patients hospitalized during the 1st wave of the epidemic in France (from the COMEBAC 1st wave study) and those of the current study | 6 months | risk factors for the various sequelae of COVID-19 |
| Association between patient characteristics and the prevalence of residual symptoms. | 6 months | effect of the therapeutic changes that occurred between the 1st and 2nd wave of COVID-19 on these persistent symptoms. |
| Association between residual symptoms and the type of SARS-CoV-2 variant | 6 months | residual symptoms of COVID-19 according to the SARS-CoV-2 variants responsible |
| Prevalence of respiratory, neurological, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19 which occurred during the 1st epidemic wave. | 6 months | residual symptoms of COVID-19 one year after COVID-19 that occurred during the 1st epidemic wave |
Countries
France
Contacts
Primary ContactTai PHAM
Outcome results
None listed